[Retracted] Pemetrexed for Recurrent Primary Central Nervous System Lymphoma in the Elderly: Results of a Retrospective Study

Table 1

Patients characteristics and therapy.

Patients	Age/gender	Position	KPS	Cycles	IT	Response	Outcome	PFS	OS
1	67/F	Primary recurrence	90	10	RT	CR	Alive	16.8+	16.8+
2	72/M	Ectopic recurrence	80	5	MTX	PR	Alive	10.2+	10.2+
3	78/M	Ectopic recurrence	80	8	MTX	PR	Death	9.2	10.3
4	82/F	Ectopic recurrence	80	4	RT	PR	Alive	8.8	10.1
5	65/F	Primary recurrence	90	3	MTX	CR	Alive	16.8+	16.8+
6	80/M	Primary recurrence	60	2	MTX	PD	Death	9.2	9.2
7	69/F	Ectopic recurrence	90	7	RT	CR	Alive	11.2+	11.2+
8	70/M	Ectopic recurrence	80	5	RT	PD	Death	9.5	9.5
9	70/M	Ectopic recurrence	80	9	MTX	CR	Alive	12.1	13.4+
10	65/F	Primary recurrence	80	11	MTX	CR	Death	7.2	9.1
11	74/M	Ectopic recurrence	90	4	MTX	PR	Death	6.2	7.8
12	76/F	Ectopic recurrence	80	8	MTX	SD	Death	2.4	2.8
13	68/F	Primary recurrence	60	7	RT	PD	Death	1.8	3.4
14	66/M	Primary recurrence	80	6	MTX	PD	Death	2.1	3.8
15	71/F	Primary recurrence	80	7	RT	PR	Alive	9.1	10.5
16	72/F	Ectopic recurrence	90	2	MTX	SD	Death	5.6	5.6
17	65/F	Primary recurrence	80	6	RT	CR	Alive	16.8+	16.8+
18	68/M	Primary recurrence	80	5	RT	SD	Death	3.4	6.1
19	75/F	Primary recurrence	60	5	MTX	PD	Death	6.6	6.6
20	69/F	Ectopic recurrence	80	7	MTX	SD	Death	4.2	5.8
21	70/F	Primary recurrence	80	9	MTX	CR	Alive	6.5	7.8+
22	77/M	Primary recurrence	60	8	RT	PD	Death	5.8	7.1
23	65/F	Metastasis	90	4	RT	SD	Alive	4.8	5.8

F, female; M, male; KPS, Karnofsky performance status; IT, initial treatment; RT, radiotherapy; MTX, methotrexate; CR, complete remission; PR, partial remission; SD, stable disease; PD, progressive disease; PFS, progression-free survival; OS, overall survival.